Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459296) titled 'Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC' on March 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: First Affiliated Hospital of Guangxi Medical University
Condition:
Nasopharyngeal Carcinoma (NPC)
Intervention:
Drug: Becotatug Vedotin
Drug: Sintilimab
Drug: Cisplatin
Radiation: intensity-modulated radiotherapy
Drug: Gemcitabine (GEM)
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: March 5, 2026
Target Sample Size: 266
Coun...